United States: Final Really Does Mean Final In The Federal Circuit

Defendants in patent infringement lawsuits often request that the United States Patent and Trademark Office ("PTO") reexamine the patent-in-suit. Patent reexamination is a process where the validity of an issued patent is again reviewed by the PTO. Patent infringement litigation, of course, takes place in federal district courts. Often, a patent infringement action brought by the patentee in federal district court and a reexamination proceeding initiated by the accused infringer in the PTO proceed at the same time. In Fresenius USA v. Baxter International1, the Federal Circuit ruled that where a reexamination and a patent infringement lawsuit involving the same patent are concurrently proceeding, the first action to reach true finality may render the other moot2. In the litigation, the Federal Circuit had earlier affirmed the trial court's judgment that the patent was infringed and not invalid, but remanded the case back to the trial court to determine damages and entitlement to injunctive relief. Before the issues of damages and entitlement to injunctive relieve were finally resolved, the PTO determined in the reexamination proceeding that the patent is invalid and the PTO determination was affirmed by the Federal Circuit. In a subsequent appeal, the Federal Circuit ruled that the reexamination trumped the litigation because the reexamination was finalized before the litigation was finalized.

Two Forums, Three Appeals, and a Complicated Procedural Background

In 2003, Fresenius filed a declaratory judgment action in federal court, seeking a judicial determination that, among other things, certain claims of the Baxter patent were invalid3. In 2006, a jury found the claims of the Baxter patent invalid4. However, the district court granted Baxter's post-trial motion for a judgment as a matter of law, finding that Fresenius had not presented sufficient evidence to support a jury verdict of patent invalidity5. The district court entered judgment in favor of Baxter. On Fresenius' appeal to the Federal Circuit in 2009, the Federal Circuit affirmed the district court's decision and remanded the case back to the district court to determine the proper amount of damages and whether to enter an injunction against Fresenius (hereinafter Fresenius I)6. In response to the Federal Circuit's remand, the district court entered a second judgment in favor of Baxter in March of 20127, and Fresenius again appealed to the Federal Circuit (hereinafter Fresenius II)8.

While the federal court litigation was proceeding, Fresenius was also pursuing a reexamination of the patent in the PTO. In 2005, two years after Fresenius filed its declaratory judgment action in federal court, Fresenius filed for ex parte reexamination of the Baxter patent9. In 2007, a PTO patent examiner issued a final rejection, finding that the claims at issue in the Baxter patent were invalid as obvious10. The examiner's decision was affirmed by the PTO's Board of Patent Appeals and Interferences ("BPAI") in 201011. Baxter timely appealed the BPAI's decision to the Federal Circuit, which, in May 2012, held that the PTO's determination of invalidity was correct12. At that time, Fresenius' appeal of the March 2012 second judgment was pending before the Federal Circuit.

On appeal in Fresenius II, Fresenius contended that Baxter no longer possessed a valid claim for patent infringement as a result of the Federal Circuit's decision to affirm the PTO's determination that the Baxter patent was invalid13. After all, if the patent was invalid, Baxter had no right to enforce it in a federal court infringement action. Thus, Fresenius asserted that Baxter's infringement action was now moot and the district court's March 2012 final judgment in favor of Baxter should be vacated and Baxter's infringement case dismissed. In contrast, Baxter noted that the issue of patent validity was previously litigated by Fresenius in the district court, and decided in Baxter's favor in the first appeal, Fresenius I. Thus, according to Baxter, because Fresenius litigated, and lost, the issue of the invalidity of the Baxter patent in Fresenius I, and because the remand to the district court was only to resolve issues unrelated to patent validity (specifically Baxter's damages and its right to an injunction), Fresenius was precluded by res judicata from using the PTO's recent determination of patent invalidity to moot Baxter's infringement case14.

The Majority Opinion – Fresenius I is Not a Final Judgment Because Other Issues Remained

As an initial matter, it is worth noting how the federal court and the PTO could reach opposite conclusions regarding the validity of the same patent. When an issued patent is challenged in federal court, the challenger, in this case Fresenius, must prove that the patent is invalid by clear and convincing evidence15. Federal courts do not actually determine whether a patent is valid –because there is already a statutory presumption of validity16 – but rather determine whether the challenger has met its burden of proving that the patent is invalid.

In contrast, in reexamination proceedings, the PTO determines invalidity (or unpatentability) by a "preponderance of the evidence" standard, a standard significantly easier to meet than the clear and convincing standard applied by federal courts17. In addition, the claim scope in a PTO reexamination may be broader than the scope determined by a federal court, because the PTO is directed by statute to give claim terms the "broadest reasonable interpretation."18 Thus, given the different burdens of proof and potential variations in claim scope, it is not surprising that in some circumstances a federal court and the PTO will come to different conclusions regarding the validity of the same patent.

Against that background, in Fresenius II, the Federal Circuit majority (Judges Dyk and Prost), framed the question presented as whether, under the patent reexam statute, the cancellation of claims by the PTO in the reexamination is binding in pending district court litigation. Whether the issue of validity was still pending in the district court turned on the issue of whether the first appeal in Fresenius ("Fresenius I"), was sufficiently "final", even though issues regarding the proper amount of damages and Baxter's right to an injunction remained pending, to preclude Fresenius from asserting the PTO's decision that the patent was invalid. The majority began its analysis by reviewing the patent reissue and reexamination statutes, and drawing out the general rule that when a claim is cancelled by the PTO in reexamination, the patent holder loses its cause of action for infringement of such claim.19 The majority also noted that there are several concepts of finality, and that the judgment in Fresenius I may be "final" for purposes of appeal, or application of res judicata in another infringement case between the same parties, but this type of finality was not dispositive of the issue presented.20

In looking at the issue of finality, the majority applied a strict standard, finding that a judgment is not sufficiently "final" to preclude an intervening PTO invalidity determination from being applied unless the earlier judgment "leaves nothing for the court to do but execute the judgment."21 The majority rejected Baxter's argument that the Fresenius I appeal was sufficiently final to prevent the PTO reexamination final judgment from being applied. According to the majority, "it could hardly be clearer that Congress meant for cancellation to terminate pending suits."22 Thus, because the Fresenius litigation in federal court was still pending, the judgment in Fresenius I (and remand solely for issues unrelated to the question of patent validity) was not "sufficiently final" to preclude Fresenius from asserting the PTO's determination of patent invalidity in the federal litigation. According to the court, "[t]he intervening decision invaliding the patents unquestionably applied in the present litigation, because the judgment in this litigation was not final."23 Because Baxter's patent was determined to be invalid, Baxter no longer possessed a viable claim against Fresenius, the infringement case was moot and the Federal Circuit remanded to the trial court with instructions to dismiss Baxter's infringement claim.24

The Dissenting Opinion – So What, Fresenius I Was a Final Decision on the Issue of Validity

Judge Newman wrote a lengthy and strongly-worded dissent. In her view, the PTO, as a non-Article III tribunal, does not have the power to overturn a final decision of the judicial branch.25 Judge Newman believes that the question of patent validity, which was decided in favor of Baxter and against Fresenius at the district court level, and then affirmed by the Federal Circuit in Fresenius I, was sufficiently "final" to preclude Fresenius from relying upon the PTO's subsequent determination of patent invalidity in the ex parte reexamination to terminate Baxter's infringement lawsuit. She noted that "Fresenius contested liability and lost, by declaratory judgment action brought in the district court, and on appeal to Federal Circuit ... The judgment of validity of the '434 patent was not subject to redetermination, and was final in all respects."26 Thus, because the issue of invalidity had been decided in Fresenius I, Judge Newman believes that the judgment is also binding upon the PTO, which can "neither invalidate, nor revive, a patent whose validity the court has adjudicated."27

Denial of Petition for Rehearing and Rehearing En Banc

Baxter subsequently petitioned the Federal Circuit for rehearing and rehearing en banc.28 The petition was denied, with several judges authoring opinions concurring or dissenting in the denial.29 Writing in support of the original panel decision (and the denial of the rehearing petition), Judges Dyk and Prost noted that under Supreme Court and Federal Circuit precedent, there are multiple concepts of "finality" of judgments.30 They further suggested that while there may have been sufficient "finality" in Fresenius I for application of res judicata to another infringement action, this type of "finality" does not support the collateral estoppel of the PTO's reexamination proceedings.31

In contrast, Judges O'Malley, Rader, Wallach and Newman dissented from the denial.32 In their view, the original panel decision was grounded on an "inapplicable and antiquated view of finality" because "none of the critical questions regarding Fresenius' liability for its past infringement of Baxter's patents remained undecided or open to debate when the PTO cancelled the '434 patent."33 "While Baxter lost its right to bring an infringement action against anyone else once the PTO acted[,] ... its right to enforce its judgment in Fresenius I was inviolate."34

Judge Newman also dissented separately from the denial, noting that an administrative agency, such as the PTO, does not have the power to override the judgment of an Article III court.35 She expressed her concern that the original panel decision "destabilizes issued patents, by ignoring the rules of finality" which may impact the value of issued patents and, thus, inventors' financial incentives to invest in ongoing research and development activities.36


In light of the Federal Circuit's decision, and the fractured denial of the rehearing en banc petition, counsel representing both patent holders and alleged infringers alike will need to weigh certain considerations, which may include venue issues (based, for example, upon the estimated length to trial in the venue), whether to seek inter partes review, and, if so, the nature and scope of the prior art selected for the inter partes review due to estoppel concerns. And if Baxter files for a writ of certiorari in the Supreme Court, we will certainly update you in our next Inside IP column.


1 Fresenius USA, Inc. v. Baxter International, Inc., Nos. 2012-1334, 1335, 2013 WL 3305736 (Fed. Cir., July 2, 2013). For ease of use, the parties will be referred to simply as "Fresenius" and "Baxter".

2 Id. at *15.

3 Id. at *1.

4 Id.

5 Id. at *2.

6 Id.

7 Id. at *3.

8 Id.

9 Id.

10 Id.

11 Id. at *4.

12 Id.

13 Id.

14 Id. at *9.

15 See, e.g., Eli Lilly and Co. v. Teva Pharmaceuticals USA, Inc., 619 F.3d 1329, 1336 (Fed. Cir. 2010).

16 35 U.S.C. § 282.

17 MPEP § 706.1.

18 See, e.g., In re NTP, Inc., 654 F.3d 1268, 1274 (Fed. Cir. 2011).

19 Id. at *5-8.

20 Id. at 9.

21 Id. at 10 (internal citations omitted).

22 Id. at 14.

23 Id. at 12.

24 Id. at 15.

25 Id. at *16-17.

26 Id. at 27.

27 Id. at 17.

28 Fresenius USA, Inc. v. Baxter Int'l, Inc., 733 F.3d 1369, 1370 (Fed. Cir. 2013).

29 Id.

30 Id. at 1371.

31 Id.

32 Id. at 1372.

33 Id. at 1381.

34 Id.

35 Id. at 1382.

36 Id.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Oblon, McClelland, Maier & Neustadt, L.L.P
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Oblon, McClelland, Maier & Neustadt, L.L.P
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions